Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and XELOX in locally advanced rectal cancer
NCT07127497Phase 2Active, not recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jun 2022
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in rectal cancer, sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Pathological Complete Response. Started Jun 2022; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07127497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07127497.